A Global Grow th Opportunit y - Squarespace
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
A G lobal G row th O ppor tunit y
1 2 / 0 7/ 2 0 1 8
DISCLAIMERS CAUTION CONCERNING FORWARD-LOOKING STATEMENTS Certain statements in this presentation may contain “forward-looking future cannabis pricing; cannabis production yields; costs of inputs; its information,” within the meaning of applicable securities laws, including the ability to market products successfully to its anticipated clients; reliance on Securities Act (Ontario) with respect to Maricann Group Inc. (“Maricann” or key personnel; the regulatory requirements; the application of federal and the “Company”). Such statements include, but are not limited to, statements provincial environmental laws; and the impact of increasing competition. with respect to expectations, projections, or other characterizations of In the case of the Company’s expected designed production capacity future events or circumstances, and our objectives, goals, strategies, beliefs, for the future phases of its expansion project facility, the expectations intentions, plans, estimates, projections and outlook, including statements of management are based on the designs and plans of the new facility, relating to our expectation with respect to our expansion project, including experience based on production at its current facility, and assumes it will be the expected increase in production, expected production cost and successfully completed, licensed and operate as planned. timing of commencement and completion of our Phase II and Phase III These forward-looking statements are also subject to the risks and expansion, expectations with respect to expanding activities in Germany uncertainties some of which are discussed in the “Risks Factors” sections and elsewhere, future growth plans, including, but not limited to, plans for and elsewhere in the Company’s annual information form dated June 19, European expansion, anticipated timing for receiving certain licenses and 2018, its short form prospectus dated March 28, 2018 and other risks certifications, including with respect to exportation/importation to and in detailed from time to time in the other publicly filed disclosure documents Germany and wholesale activities in Germany, expectations with respect to of the Company which are available at www.sedar.com. Forward-looking the renewal of licenses, expectations with respect to increased production statements are not guarantees of future performance and involve risks, capacity and timing and quantum of distribution activities; medical benefits, uncertainties, and assumptions which could cause actual results to differ viability, safety, efficacy, and social acceptance of cannabis, expectations materially from the conclusions, forecasts, or projections anticipated in in respect to anticipated trends and challenges in the Company’s industry, these forward-looking statements. Because of these risks, uncertainties, its business and the markets in which it operates, commentaries related to and assumptions, the reader should not place undue reliance on these legalization of marijuana and time related thereto, and our other plans and forward-looking statements. The Company’s forward-looking statements objectives, or estimates or predictions of actions of customers, suppliers, are made only as of the date of this presentation, and except as required competitors or regulatory authorities. These statements are subject to by applicable law, Maricann undertakes no obligation to update or revise certain risks, assumptions and uncertainties that could cause actual results these forward-looking statements to reflect new information, future events to differ materially from those included in the forward-looking statements. or circumstances. The words “believe”, “plan”, “intend”, “estimate”, “expect”, or “anticipate”, and similar expressions, as well as future or conditional verbs such as “will”, Additional information regarding Maricann Group Inc. is available “should”, “would”, and “could” often identify forward-looking statements. We on our website at www.maricann.com or through the SEDAR have based these forward-looking statements on our current views with website at www.sedar.com. respect to future events and financial performance. With respect to forward looking statements contained in this Presentation, the Company has made assumptions and applied certain factors regarding, among other things: 2
GLOBAL DEMAND
$1 8 0 B I LLI O N 3
Global Medical Market
$ 8 .7 B I LLI O N 2
Canadian Recreational Market
$1 . 3 B I LLI O N 1
Canadian Medical Market
1 . 2024 , H ealth Canada
2 . D eloit te ,“ Re creatio nal M arijuana I nsig hts and O p p o r tunities ”.
3 . Various sources
3
C A P I TA L I Z I N G O N O P P O R T U N I T Y
ALBERTA — AGLC
Allocating up to 3,375 kg of
cannabis product for the AB Manitoba — MBLL
market within the first six months. Supply agreement to make
available for purchase at least
550,000 grams of various
cannabis products.
BRITISH COLUMBIA — BCLDB
Entered into a memorandum of
understanding (“MOU”) to initially
supply approximately 3,621,900
grams of non-medical cannabis.
4
EUROPEAN GROWTH MARKETS
Addressing the existing $3B CBD market in Europe
LEG AL
MEDICAL ONLY
DECRIMINALI Z ED
16,000 PATIENTS
Up from ~800 in 2016 to
ILLEG AL 16,000 currently
62%
Have qualified for full health
insurance reimbursement
GROWING CBD MARKET
Existing operations in a suburb of
Zurich; selling product into a fast
FINISHED DOSE
growing CBD market
MANUFACTURING
Maricann entered into
a non-binding LOI with
Malta Enterprise
5
Licensed Production
GLOBAL PRESENCE
Imports from Canada
Geographically diverse with operations in Canada and Western Europe
Research Center
GERMANY - Ebersbach Facility
CANADA - Langton Facility
Proposed 820,000 square feet of
217,000 square feet of grow clean-room cultivation, processing,
and production space with and extraction
annual capacity to grow up
to 36,000 kg1 . Expansion
plans underway to increase
capacity up to 105,000 kg1
Switzerland - Haxxon AG
Malta - Malta Enterprise
~60,000 square feet of
Independantly secured
facility for female hemp
Letter of Intent (LOI) with
cultivation
Malta Enterprise
1. Based on current production at existing facility adjusted to reflect 635,000 square foot facility
6
CANADA
Langton is a low-cost high-efficiency facility
Phase 1 Phase 2
• 217,000 square feet of • Additional 635,000
grow and production square feet of grow space
space with annual capacity bring annual capacity up
to grow up to 36,000 kg1 to 105,000 kgs1
• Phase One will be fully
operational in Q4 of 2018
Langton is a low-cost high-efficiency facility with a natural
gas well and cogeneration facility on site, in addition to
having all water recycled through a bio-pond. As an added
bonus, due to automation, our labour force will be at a
fraction of the costs of our competitors.
1. Based on current production at existing facility adjusted to reflect 635,000 square foot facility
7
GERMANY
Import and Narcotics Wholesale license to be issued in Q3 of 2018
Location Room to Grow
EU-GMP Compliant – located near Dresden, Proposed 820,000 square feet of clean-room
Germany. cultivation, processing, and extraction. 164 Hectares
(~405 acres) of outdoor industrial hemp cultivation
Growing Markets Price Point
The German patient population is growing 62% of patients have qualified for full health
exponentially – Up to over 16,0001 patients from insurance reimbursement2
~800 in 2016
1. https://internationalcbc.com/medical-cannabis-community-growing-rapidly-in-germany/
2. https://phil420.com/2018/01/14/german-media-reports-dramatic-increase-in-cannabis-patients-covered-by-insurance-marguerite-arnold/
8
SWITZERLAND
Maricann acquired HAXXON AG in May of 2018
Coming Soon
Maricann will be launching our own
line of hemp cigarettes in Q4 of 2018
Producing
Currently producing out of a 60,000
square foot facility in Regensdorf,
Switzerland just outside of Zurich
Scaling Up
Plans to upgrade the facility and
increase production by a factor of 6
9
CORE BRANDS
KI W I R A R E DA N KN ESS H I G H TI D E
Simple, Concise, Approachable Bold, Daring, Authentic, Original Powerful, Refined, Self-Assured
In the past the world of Cannabis has Our first partnership brand, Rare High Tide is HIGH QUALITY POWER.
existed in what seemed to be hidden Dankness optimizes bold and Just like the high tide of the ocean,
code. Non-users nervously thinking “I authentic strains of the highest High Tide Cannabis is not to be
don’t want to even ask that because quality. Those who are experienced messed with. It goes to great lengths
I’ll sound stupid”. Well, Kiwi is going to in the cannabis space and follow with no expense spared, to harness
shed some much needed light on all industry events like the “Cannabis the power of fine cannabis and bring
things cannabis. Think Cannabis 101. It Cup” will know of its legendary it to those who have the ability to take
will be the brand that people will look potency and unbelievable cerebral it on. It’s no shrinking violet and never
to for simple, easy and fun solutions effects. This is not for the uninitiated, backs down from a fight. It brims with
to their cannabis questions. It will use but rather the bold and experienced confidence. It knows how good it is.
simple language, void of acronyms, cannabis consumers who wants to And knows that’s it untouchable when
jargon and idioms when it can. push the limits of what’s possible. it comes to strength and quality.
10T E C H N O L O G I C A L D I F F E R E N T I AT I O N
01
01 02
02 03
03
01
01 02
02 03
03
We’ve brought the best of the pharmaceutical world to cannabis. VESIsorb is used in lipophilic drugs (fat soluble) around
the world and Marciann has the global right for use with cannabis, patent protected. With both medicinal and recreational
VESIsorb
VESIsorb CANNABINOIDS
CANNABINOIDS
applications for products such as beverages, edibles, capsules, and transdermal products, VESIsorb allows for consistent
and predictable dosing with rapid onset and greater absorption. VESIsorb
VESIsorb CANNABINOIDS
CANNABINOIDS
VESIsorbprovides
VESIsorb providesMariCann
MariCannwith
withthe
theopportunity
opportunitytototruly
truly Cannabinoidsare
Cannabinoids areoily
oilymolecules
moleculesfrom
fromthe
thecannabis
cannabisplant
plant
differentiateitsitsmedical
differentiate medicalcannabis
cannabisproducts.
products.
02
03 03
04 05
04 05 06
06 07
07
VESIsorb
VESIsorbprovides
providesMariCann
MariCannwith
withthe
theopportunity
opportunitytototruly
truly Cannabinoids
Cannabinoidsare
areoily
oilymolecules
moleculesfrom
fromthe
thecannabis
cannabisplant
plant
differentiate
differentiateitsitsmedical
medicalcannabis
cannabisproducts.
products.
EFFECT
EFFEC
03
03 04
04 05
05 06
06 07
07
CANNABINOIDS CANNABINOIDS
EFFECTS
EFFEC
CANNABINOIDS CANNABINOIDS
CANNABINOIDS
CANNABINOIDS
CANNABINOIDS
CANNABINOIDS
eortunity
cannabistoplant
truly Cannabinoids are oily molecules from the cannabis plant When cannabinoids are ingested, they
they
When tend
tendtotoclump
cannabinoids clumptogether
are togetherininthe
ingested, thewater-based
water-basedenvironment
environment This
Thisclumping
clumpinginterferes
interfereswith
withabsorption
absorption Poorly
Poorlyabsorbe
absorb
s. Cannabinoids are oily molecules When cannabinoids are ingested.. they tend to clump together in the
ofofthe
thedigestive
digestivesystem
system This clumping interferes with
from
06
07 the cannabis plant 07
08 digestive
0809
09
system 10
absorption
10 1111
e
cannabis
cannabis
plant
plant When
Whencannabinoids
cannabinoidsare
are
ingested,
ingested, they
theytend
tendtotoclump
clumptogether
togetherininthe
thewater-based
water-basedenvironment
environment This
Thisclumping
clumpinginterferes
interfereswith
withabsorption
absorption Poorly
Poorlyabsorbe
absorb
ofofthe
thedigestive
digestivesystem
system
EFFECTS EFFECTS ACTIVE BLOOD
ACTIVE CANNABINOID
BLOOD LEVEL
CANNABINOID LEVEL RATE
RATO
07
07 08
08 09
09 10
10 1111
EFFECTS
EFFECTS ACTIVE BLOOD
ACTIVE CANNABINOID
BLOOD LEVEL
CANNABINOID LEVEL RATE O
RATE
TIME
TIME
based environment This
Poorly
clumping
absorbed
interferes
cannabinoids
with absorption
can have unpredictable effects Poorly
VESIsorb
absorbed
technology
cannabinoids
allows cannabinoids
can have unpredictable
to disperse effects
more VESIsorb
More technology
Moreuniform
uniform allows cannabinoids
distribution
distributionmeans
meansmore to
moreof disperse
ofthe
thedrug more
drugcan
canmake
make This
Thistechnology
technologymimics
mimicsthe
thebody's
body'snatural
naturalprocesses,
processes,providing
providing more
morereliable
reliabler
evenly after ingestion evenly after
contact
contact ingestion
with absorptive
with absorptivemembranes
membranes higher
higherand
andmore
moreimmediate
immediateactive
activelevels
levelsofofblood
bloodcannabinoids,
cannabinoids,
TIME
TIME
10
11 1112 121313 14
14 1515
Poorly
Poorlyabsorbed
absorbedcannabinoids
cannabinoidscan
canhave
haveunpredictable
unpredictableeffects
effects VESIsorb
VESIsorb technology
technology allows
allows
cannabinoids
cannabinoids
toto
disperse
disperse
more
more More
Moreuniform
uniformdistribution
distributionmeans
meansmore
moreofofthe
thedrug
drugcan
canmake
make This
Thistechnology
technologymimics
mimicsthe
thebody's
body'snatural
naturalprocesses,
processes,providing
providing more
morereliable
reliablera
Poorly absorbed cannabinoids
ACTIVE
RATE OF
BLOOD
ABSORPTION
CANNABINOID LEVEL
VESIsorb technology allows more
evenly
evenlyafter
after
ingestion
ingestion
RATE OF ABSORPTION
More uniform distribution means
contact
contactwith
withabsorptive
absorptivemembranes
membranes This technology mimics the
higher
higherand
andmore
moreimmediate
immediateactive
activelevels
levelsofofblood
bloodcannabinoids,
cannabinoids,
can have unpredictable effects
1111
evenly dispersal after ingestion
1212
the
13 drug can make contact with
13 14
14body’s natural processes, 1515
THERAPEUTIC POTENTIAL
absorptive membranes THERAPEUTIC POTENTIAL
providing higher and more LESS DRU
LESS
MATER
D
MATERIAL
RATE
RATE OFOF ABSORPTION
ABSORPTION
immediate active levels of blood
cannabinoids, more reliable rates LESS DRUG
LESS
MATERIAL
DR
MATERIA
THERAPEUTIC
THERAPEUTIC
POTENTIAL
POTENTIAL
of absorption
TIME
al
theprocesses,
drug can providing
make This
moretechnology
reliable rates
mimics
of absorption
the body's natural processes, providing more
and increased
reliable rates
therapeutic
of absorption
potential. and increased
VESIsorb
VESIsorb therapeutic
also allows
also potential.
allowsmore
moreofofthe
theingested
ingesteddrug
drugtotobe
beabsorbed
absorbed before
beforebeing
beingbroken
brokendown
downbybythe
theliver
liver Less
Lessdrug
drugmate
ma
of blood cannabinoids, higher and more immediate active levels of blood cannabinoids, which
whichcan
cantran
tra
11 14
15 15
16 16
al
processes,
processes,
providing
providing more
morereliable
reliable
rates
rates
ofof
absorption
absorption and
andincreased
increased
therapeutic
therapeutic
potential.
potential. VESIsorb
VESIsorbalso
alsoallows
allowsmore
moreofofthe
theingested
ingesteddrug
drugtotobe
beabsorbed
absorbed before
beforebeing
beingbroken
brokendown
downbybythe
theliver
liver Less
Lessdrug
drugmate
matWORLD LEADING EFFICIENCY IN PRODUCTION
AI-DataGrow Rockwell Automation Energy Efficiencies
We capture all data; every drop of water We are the first to take standard off Natural gas cogeneration facility on site,
that goes to each plant, light cycles, the shelf automation and customize reduces electricity costs. All energy
nutrients, humidity, temperature, and can the software to create an automated from one source, heat, electricity, and
build from this data to optimize future cultivation facility, resulting in ultra high Co2. All water is recycled through a
production, perfecting the environment quality product. The master grower, state-of-the-art biofilter
and grow cycle. without the human element. Your AI
Master Grower.
12P H A R M A C Y I N I T I AT I V E
Partnerships National
We’ve teamed up with national and Canada-wide participation through a
regional pharmacy operators large retail banner network
Education Training
We offer programming for patients Pharmacists are trained in the field
and healthcare professionals of medicinal cannabis to better serve
their customers
13THE MARICANN TEAM
CEO & Director President CFO VP of Sales & Marketing
Benjamin Ward Terry Fretz Scott Langille Geoff Kosar
Ben leads all facets of the Terry Fretz is a long-time Scott has over 30 years of Geoff has played a key role
company’s operations, including pharmaceutical executive, Terry experience in the pharmaceutical in shaping the marketing and
its strategic direction and was integral in establishing and industry in both Canada and the strategic direction of many iconic
execution, finance and industry running two privately held generic United States. Scott has held household brands in Canada for
relations. He brings extensive pharmaceutical companies. CFO positions at publicly traded the past 20 years. Most recently,
domestic and global experience Under his leadership, both pharmaceutical companies he was the Head of Marketing at
in business development, organizations were recognized including Tribute Pharmaceuticals, Diageo, Canada’s largest Spirits
infrastructure development and as the fastest growing pharma and Virexx Medical Corp. Past company. Geoff understands
capital markets to his leadership companies in Canada. Both financial experience includes selling and marketing brands in
of Maricann. Ben holds a BA companies were subsequently Vice President at Biovail regulated industries.
(Honors) and an MBA from acquired by publicly traded Pharmaceuticals Inc. and
Bradford University School of multinationals. Terry served as Director, Corporate Finance
Management (England), the President and General Manager at Biovail Corporation. Scott
latter with a dual concentration in of Watson Pharmaceuticals – has a professional accounting
Operations and Finance. Canada before assuming his designation and an MBA from the
responsibilities as President at University of Toronto.
Maricann.
14THE MARICANN TEAM
Director, Investor Relations Vice President, Global Director, Pharmacy National Sales Director
Infrastructure Project Management
Graham Farrell Jeff Ayotte Veronica Lesch Sanjay Patel
Graham has been deeply involved Jeff leads Maricann’s Global Veronica has 20 years Sanjay is responsible for leading
with the capital markets for more Infrastructure which include of experience in project our commercial sales strategy for
than 15 years. Prior to joining the Company’s Engineering management and supply chain both the recreational and medical
Maricann, Mr. Farrell worked in and Construction departments. in pharmaceutical, consumer markets in Canada. Sanjay brings
every aspect of the investment Over 18 years of experience packaged goods and retail with him a successful track
banking business, from running an delivering successfully complex pharmacy industries, including record of selling to Liquor Boards
equity trading desk to financing infrastructure projects while Apotex, Johnson & Johnson and private beverage alcohol
public companies. Graham providing major returns on and Shoppers Drug Mart. As customers in Canada. Sanjay has
studied Political Science at the investment. Jeff’s successful an operational leader, she has worked with both Diageo Canada
University of Waterloo. deliveries include industry sectors proven successes within fast- and Molson Coors Canada, in
such as Pharmaceutical, Medical, paced dynamic environments in various roles including sales,
Food and Beverage, and Energy both domestic and international business analytics and strategy.
conservation initiatives with markets. Veronica is PMP Sanjay holds a Bachelors of
Hospitals and Universities. Jeff’s certified and holds a BA (Honors) Science in Management (BSM)
global reach has contributed from Trinity College, University of degree, with a concentration in
to the design, engineering, and Toronto. Finance, from the University of
construction of various cannabis Massachusetts, and an MBA from
facilities around the world. the Schulich School of Business.
15THE MARICANN TEAM
Interim Chair Director Director Director
Paul Pathak Michael Stein Gerhard Müller Eric Silver
Paul Pathak is a partner at Chitiz Michael Stein currently acts Past partner of Ernst and Young’s With extensive experience using
Pathak LLP, a Toronto law firm. as a financial consultant and German practice, Gerhard was medical cannabis to treat chronic
Paul practices principally in the advises clients on various responsible for the Technology, pain, Dr. Silver co-founded L.E.
areas of corporate, securities, matters, including acquisitions, Media & Entertainment sector at Medical in 2002, a nutraceutical
corporate finance, mergers and divestitures, corporate Ernst & Young for the Germany, and natural health supplement
acquisitions and commercial financings, reorganizations Switzerland, Austria (GSA) Region. company. Dr. Silver is an Assistant
law. He represents and provides and restructurings. Mr. Stein is Gerhard is a Certified Public Professor and Clinical Teacher
sophisticated guidance to private currently the President, Secretary Auditor and Tax consultant who in the Department of Family
and public corporate clients and director of Applied Inventions studied economics and English in and Community Medicine at the
in a broad range of industries, Management Corp. He is former Munich and Manchester (UK). He University of Toronto. He is a
including mining, technology, Director of U.S. Money Market is the deputy chairman of m4e AG, member of the College of Family
cannabis, manufacturing, venture for a federally chartered Trust a German listed Media company. Physicians of Canada, with a
capital and merchant banking. company and former institutional Gerhard is an independent focused practice in interventional
money banker for a U.S. Savings member of the company’s Board pain management.
and Loan Association based in of Directors.
California. Mr. Stein majored in
economics and graduated with
a Bachelor of Arts from York
University.
16MARICANN GMBH ADVISORY BOARD
Medical Public Policy Legal Insurance, Technology
Professor Dr. Markus Birgit Homburger Dr. Horst Schiessl Hans Dendl
Backmund MD, PhD Currently heading the Berlin office Member of the Board of Past Chairman of AOK Health,
Chair of German Society of of the Deutsche Aktieninstitut the Dussmann Stifting and Researcher at NASA Jet
Addiction Medicine, Professor e.V and senior advisor in an Independent Chair of the Propulsion Laboratory (JPL), and
of Medicine Ludwig Maximilians international executive search supervisory board of Baader Lockheed Martin Aeronautical
Universtät Munchen, Head of company. Ms. Homburger is the Bank AG. Dr. Schiessl, founding Research. Mr. Dendl is currently
PIT, Editor of the magazine recent past chair of the Freie partner of SSP Schwiessl, is a lecturer at Ludwig Maximilians
Suchtmedizin (Journal of Demokratische Partei, member of a lawyer with more than forty Universtät Munchen (LMU) —
Addiction Medicine), President of the Federal Coalition committee, years of experience in consulting MSc. He holds a degree from
the interdisciplinary congress of member of the Bundestag up and advising larger German the Massachusetts Institute of
Addiction Medicine, Munich (800 to 2013, Chairwoman of the companies and family offices. He Technology (MIT)
Medical Doctors) and various FDP parliamentary group in studied law and economics in
other positions mainly relating to the Bundestag, and leader of Munich.
addiction research and drug and the parliamentary group with
alcohol dependency. 93 members of the German
Bundestag, responsible for over
110 staff.
17R E C E N T U P D AT E S
PROVINCIAL AGREEMENTS
Manitoba
Maricann is pleased to announce that on June 28, 2018, the Company signed a supply
agreement with the Manitoba Liquor & Lotteries Corporation (“MBLL”) to make available for
purchase by MBLL at least 550,000 grams of various cannabis products during the first
twelve months of the agreement.
Alberta
Maricann is pleased to announce that they have entered into an agreement with the
Alberta Gaming, Liquor & Cannabis Commission (AGLC) to allocate up to 3,375 kg of
cannabis product for the AB market within the first six months.
British Columbia
Maricann is pleased to announce that it has been selected by the BC Liquor Distribution
Branch (“BCLDB”) to enter into a memorandum of understanding (“MOU”) as a preferred
licensed producer to initially supply approximately 3,621,900g (~3,622kg) of non-medical
cannabis to BCLDB over the first 12 months following legalization.
FA C I L I T Y U P D AT ES
Langton Facility Expansion
Construction on the expansion of the Company’s facility at 138 8th Concession Road,
Langton, Ontario (the “Langton Facility’) is continuing to progress. By mid-November, 2018
(subject to receipt of the applicable licenses from Health Canada), Maricann expects to
be capable of producing 706kg of dried cannabis per week in Phase 1 of the expansion of
its Langton Facility. By April 2019, Maricann expects to be capable of producing 2,023kg
of dried cannabis per week assuming building permits, long lead items, such as HVAC
equipment are delivered on time, at its Langton Facility.
18C O N TA C T I N F O R M AT I O N
Maricann Group Inc.
Graham Farrell
Director, Investor Relations
graham@maricann.com
647-643-7665
Corporate Headquarters (Canada)
Maricann Group Inc.
845 Harrington Court, Unit 3
Burlington, Ontario L7N 3P3
Canada
289-288-6274
European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen
Deutschland
maricann.com
19You can also read
